Geode Capital Management LLC Buys 2,768 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Geode Capital Management LLC grew its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 0.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,766,370 shares of the biotechnology company’s stock after purchasing an additional 2,768 shares during the period. Geode Capital Management LLC owned approximately 1.23% of Aurinia Pharmaceuticals worth $12,947,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of AUPH. SG Americas Securities LLC lifted its stake in shares of Aurinia Pharmaceuticals by 4,307.9% during the 3rd quarter. SG Americas Securities LLC now owns 547,727 shares of the biotechnology company’s stock worth $4,015,000 after acquiring an additional 535,301 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Aurinia Pharmaceuticals during the 3rd quarter worth approximately $3,330,000. Stonepine Capital Management LLC bought a new stake in shares of Aurinia Pharmaceuticals during the 2nd quarter worth approximately $1,713,000. AQR Capital Management LLC bought a new stake in shares of Aurinia Pharmaceuticals during the 2nd quarter worth approximately $1,155,000. Finally, Barclays PLC lifted its stake in shares of Aurinia Pharmaceuticals by 187.6% during the 3rd quarter. Barclays PLC now owns 219,331 shares of the biotechnology company’s stock worth $1,607,000 after acquiring an additional 143,072 shares during the last quarter. 36.83% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Jeffrey Allen Bailey sold 4,557 shares of Aurinia Pharmaceuticals stock in a transaction on Monday, November 11th. The stock was sold at an average price of $8.43, for a total value of $38,415.51. Following the transaction, the director now directly owns 13,356 shares in the company, valued at approximately $112,591.08. This trade represents a 25.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 4.30% of the company’s stock.

Analyst Upgrades and Downgrades

AUPH has been the subject of a number of research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $10.00 price target on shares of Aurinia Pharmaceuticals in a research note on Monday, September 16th. StockNews.com downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, December 13th. Finally, HC Wainwright restated a “buy” rating and set a $13.00 price objective on shares of Aurinia Pharmaceuticals in a report on Friday, September 6th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Aurinia Pharmaceuticals Trading Down 0.3 %

Shares of NASDAQ:AUPH opened at $9.17 on Tuesday. Aurinia Pharmaceuticals Inc. has a 12-month low of $4.71 and a 12-month high of $10.67. The business’s fifty day simple moving average is $8.50 and its 200-day simple moving average is $7.05. The company has a market capitalization of $1.31 billion, a PE ratio of -61.13 and a beta of 1.41. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.